Amylyx Pharmaceuticals Inc (AMLX): Price-to-Sales Ratio
The price-to-sales ratio change for Amylyx Pharmaceuticals (AMLX) correlates with the production of neurodegeneration medications in the US, where -2318.10 becomes the new value for this metric. Business stability is bolstered by the development of treatments for ALS and Alzheimer's to mitigate regulatory risks. Furthermore, the implementation of robotic molecule screening accelerates the search for new compounds, optimizing laboratory processes.
%20P%2FS%20Multiple&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_AMLX_-_Amylyx-Pharmaceuticals_-_PS-Multiple "AMLX - Amylyx Corp Market Capitalization-to-Revenue Ratio over the range 07/04/2022 - 03/04/2026 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Amylyx (AMLX)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- balance sheet net asset value indicators:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Amylyx Corp|AMLX - Company Aggregate Debts|Debts to Book Capitalization Amylyx|AMLX - Company Long-Term Debts|Company Current Liabilities Amylyx Pharmaceuticals|Immediate Liquidity amylyx.com
- earnings and valuation multiples information:
AMLX - Net Income|Projected Future Earnings Amylyx Pharmaceuticals|AMLX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Amylyx Pharmaceuticals Inc|AMLX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Amylyx|AMLX - Operating profit EBITDA|Net earnings per share for the last 12 months Amylyx Pharmaceuticals|AMLX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth amylyx.com|AMLX - Earnings per share growth in current year|Net earnings per share growth forecast for next year Amylyx Pharmaceuticals
- issuer revenue and sales details:
General company analysis:AMLX amylyx.com
The P/S ratio determines the market value of a business relative to its revenue, allowing for an assessment of the premium paid per unit of product sold. By analyzing P/S volatility, an investor can identify the impact of regulatory approvals on the capitalization of Amylyx Pharmaceuticals (AMLX), as demand remains stable in the non-cyclical neurology sector, and sharp changes in the metric typically signal successful clinical trials.
Competing companies
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC (Regencell Bioscience Ltd) - Price-to-Sales Ratio|Axsome Therapeutics Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|vikingtherapeutics.com (VKTX) - P/S Multiple|Price-to-Revenue Ratio Supernus|CPRX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Market Cap to Revenue Harmony Corp HRMY|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple trevitherapeutics.com TRVI|Praxis Precision Medicines, Inc. - P/S Multiple|Anavex (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Price to Sales Prothena Corp (PRTA)|Market Cap to Revenue ALEC|P/S Multiple annexonbio.com|Market Cap to Revenue OMER (Omeros Corporation)|Market Cap to Sales Volume NGNE|P/S Multiple ACIU (AC Immune Corp)|Price-to-Revenue Coefficient Voyager Corp (VYGR)|Neumora Therapeutics - P/S Multiple|scilexholding.com (SCLX) - Market Cap to Revenue|TVGN: P/S Multiple|Alpha Cognition Inc. (ACOG) - P/S Multiple|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|Price-to-Revenue Ratio IKT|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|Price-to-Revenue Coefficient assertiotx.com|P/S Multiple COYA (Coya Therapeutics)|P/S Multiple VistaGen Therapeutics, Inc. VTGN|OVID - Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Revenue|CervoMed Inc. (CRVO) - Price-to-Revenue Ratio|ATHE (Alterity Therapeutics Limited) - Price-to-Revenue Ratio|Market Cap to Revenue CLNN|Market Cap to Revenue Ratio PEPG (PepGen Corp)|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|Relmada Corp - Market Cap to Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Price to Sales|AIFF: Market Cap to Revenue|KLTO - P/S Multiple|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Reviva Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio MetaVia Inc.|Price to Sales neuraxis.com NRXS|P/S Multiple HSDT|P/S Multiple passagebio.com (PASG)|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV - Market Cap to Revenue|ATHA: Market Cap to Revenue|Price to Sales addextherapeutics.com|alzamend.com (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics, Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|Price to Sales Pasithea KTTA|Market Cap to Revenue CRGT (Cortigent, Inc.)|avenuetx.com - Market Cap to Revenue Ratio|BrainStorm Cell Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CARA|CHRO - Price-to-Revenue Ratio|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|longboardpharma.com - Market Capitalization-to-Revenue Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|P/S Multiple NKGen Biotech Inc|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN - Market Cap to Revenue|Vigil Neuro - P/S Multiple|WENA - P/S Multiple|CERE: P/S Multiple
